How would rare-disease carveouts affect Medicare drug-pricing pilot savings?

New research cited by STAT found that excluding rare-disease therapies from a Medicare pilot aimed at lowering drug prices would erase much of the projected savings from retail drugs. The article says such exemptions may be politically appealing, but they would materially weaken the pilot’s fiscal impact.